# US 2023/0398114 A1 · Methods of treating coronavirus disease and compounds for same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398114 A1
- Document ID: US20230398114A1
- Status: Published application
- Kind: A1
- Application number: 18/035,011
- Filed: 2021-11-02
- Published: 2023-12-14
- Earliest claimed: 2020-11-02
- Applicants: Skymount Medical US Inc.; The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Inventors: Kishor M. WASAN; Chris GALLIANO; Supratik MUKHOPADHYAY; Adam BESS; Frej Knut Gosta BERGLIND; Stephania CORMIER; Allan ADER; Nicholas GRIGGS; Janet GOULD; Tiffany CHO; Julia ABRAMOV; Peter HNIK; Michal BRYLINSKI
- Web page: https://patentgrep.com/patent/US20230398114A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/609: Amides, e.g. salicylamide {(labetalol, metoclopramide A61K31/166)}
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A tyrosine kinase inhibitor for use in the treatment of COVID-19 and/or its associated symptoms. Also disclosed is a method of treating an individual infected with a coronavirus, wherein said method comprises the steps of: providing a tyrosine kinase inhibitor; and administering said tyrosine kinase inhibitor to said individual in a dosage amount sufficient to prevent/stabilize/reduce the risks and/or symptoms associated with a coronavirus infection.

## Claims

### Claim 1

A method of treating a subject exposed to a coronavirus, the method comprising steps of:
(a) providing a therapeutically effective amount of a tyrosine kinase inhibitor; and
(b) administering the therapeutically effect amount to the subject,
wherein the treating comprises ameliorating and/or inhibiting some or substantially all of the symptoms of a coronavirus-related disease in the subject.

### Claim 2 (depends on 1)

The method of claim 1, further comprising a step of providing a second therapeutically effective amount of a second tyrosine kinase inhibitor and a step of administering the second therapeutically effective amount to the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tyrosine kinase inhibitor is one of Axitinib; Mebendazole; Crizotinib; Bosutinib; Vandetanib; Midostaurin; Gefitinib; Niclosamide; Imatinib; Dabrafenib; Entrectinib; Sorafenib; Dacomitinib; Sunitinib; Alectinib; Baricitinib; or Ibrutinib.

### Claim 4 (depends on 2)

The method of claim 2, wherein the second tyrosine kinase inhibitor is one of Axitinib; Mebendazole; Crizotinib; Bosutinib; Vandetanib; Midostaurin; Gefitinib; Niclosamide; Imatinib; Dabrafenib; Entrectinib; Sorafenib; Dacomitinib; Sunitinib; Alectinib; Baricitinib; or Ibrutinib.

### Claim 5 (depends on 1)

The method of claim 1, wherein the tyrosine kinase inhibitor is Mebendazole.

### Claim 6 (depends on 5)

The method of claim 5, wherein the therapeutically effective amount is between about 25 mg and about 500 mg per day.

### Claim 7 (depends on 5)

The method of claim 5, wherein the therapeutically effective amount is between about 175 mg and about 225 mg per day.

### Claim 8 (depends on 1)

The method of claim 1, wherein the tyrosine kinase inhibitor is Imatinib.

### Claim 9 (depends on 8)

The method of claim 8, wherein the therapeutically effective amount is between about 500 mg and about 1200 mg per day.

### Claim 10 (depends on 8)

The method of claim 8, wherein the therapeutically effective amount is between about 700 mg and about 1000 mg per day.

### Claim 11 (depends on 2)

The method of claim 2, wherein the tyrosine kinase inhibitor is Mebendazole and the second tyrosine kinase inhibitor is Imatinib.

### Claim 12 (depends on 11)

The method of claim 11, wherein the effective amount is between about 25 mg and about 500 mg per day and the second effective amount is between about 500 mg and about 1100 mg per day.

### Claim 13 (depends on 1)

The method of claim 1, wherein the coronavirus is SARS-CoV-2 or a variant thereof.

### Claim 14

A method of forming a target cell/agent complex, the method comprising steps of:
(c) administering the therapeutically effect amount of the agent to the target cell; and
(d) forming the target cell/agent complex,
wherein the target cell/complex inhibits fusion of a coronavirus with the target cell, inhibits entry of the coronavirus into the target cell and/or inhibits replication of the coronavirus within the target cell.

### Claim 15 (depends on 14)

The method of claim 14, wherein the agent comprises a tyrosine kinase inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the tyrosine kinase inhibitor is one of Axitinib; Mebendazole; Crizotinib; Bosutinib; Vandetanib; Midostaurin; Gefitinib; Niclosamide; Imatinib; Dabrafenib; Entrectinib; Sorafenib; Dacomitinib; Sunitinib; Alectinib; Baricitinib; or Ibrutinib.

### Claim 17 (depends on 14)

The method of claim 14, wherein the agent comprises Mebendazole.

### Claim 18 (depends on 17)

The method of claim 17, wherein the therapeutically effective amount is between about 75 nM to about 2100 nM.

### Claim 19 (depends on 17)

The method of claim 17, wherein the therapeutically effective amount is between about 100 nM and 2000 nM.

### Claim 20 (depends on 14)

The method of claim 14, further comprising a step of administering a second therapeutically effect amount of a second agent to the target cell and a step of forming a second target cell/complex.

### Claim 21 (depends on 20)

The method of claim 20, wherein the second agent is a second tyrosine kinase inhibitor.

### Claim 22 (depends on 21)

The method of claim 21, wherein the second tyrosine kinase inhibitor is one of Axitinib; Mebendazole; Crizotinib; Bosutinib; Vandetanib; Midostaurin; Gefitinib; Niclosamide; Imatinib; Dabrafenib; Entrectinib; Sorafenib; Dacomitinib; Sunitinib; Alectinib; Baricitinib; or Ibrutinib.

### Claim 23 (depends on 20)

The method of claim 20, wherein the second agent comprises Imatinib.

### Claim 24 (depends on 23)

The method of claim 23, wherein the second therapeutically effect amount is between about 5 nM to about 120 nM.

### Claim 25 (depends on 23)

The method of claim 23, wherein the second therapeutically effective amount is between about 10 nM and 100 nM.

### Claim 26 (depends on 14)

The method of claim 14, wherein the coronavirus is SARS-CoV-2 or a variant thereof.

### Claim 27 (depends on 14)

The method of claim 14, wherein the target cell is an epithelial cell of the upper airways and conducting airways (ciliated and non-ciliated); an alveolar epithelial cell (either type 1 or 2); an epithelial cell of the olfactory system, a neuron of the olfactory system; a neuron of the central nervous system, a neuron of the peripheral nervous system; an epithelial cell of the gastrointestinal tract, an enteroctyte of the gastrointestinal tract, a gland cell of the gastrointestinal tract; a white blood cell, a red blood cell, a thrombocyte, an immune effector cell; a cardiovascular cell, and a renal cell.

### Claim 28

Use of a tyrosine kinase inhibitor for treating a subject exposed to a coronavirus or infected with a coronavirus.

### Claim 29 (depends on 28)

The use of claim 28, further comprising use of a second tyrosine kinase inhibitor.

### Claim 30 (depends on 28)

The use of claim 28, wherein the tyrosine kinase inhibitor is one of Axitinib; Mebendazole; Crizotinib; Bosutinib; Vandetanib; Midostaurin; Gefitinib; Niclosamide; Imatinib; Dabrafenib; Entrectinib; Sorafenib; Dacomitinib; Sunitinib; Alectinib; Baricitinib; or Ibrutinib.

### Claim 31 (depends on 29)

The use of claim 29, wherein the tyrosine kinase inhibitor and the second tyrosine kinase inhibitor are each one of: one of Axitinib; Mebendazole; Crizotinib; Bosutinib; Vandetanib; Midostaurin; Gefitinib; Niclosamide; Imatinib; Dabrafenib; Entrectinib; Sorafenib; Dacomitinib; Sunitinib; Alectinib; Baricitinib; or Ibrutinib.

### Claim 32 (depends on 28)

The use of claim 28, wherein the tyrosine kinase inhibitor is Mebendazole.

### Claim 33 (depends on 29)

The use of claim 29, wherein the tyrosine kinase inhibitor is Mebendazole and the second tyrosine kinase is Imatinib.

### Claim 34 (depends on 28)

The use of claim 28, the coronavirus is SARS-CoV-2 or a variant thereof.
